The report provides a detailed analysis essential for establishing a tirbanibulin production plant. It encompasses all critical aspects necessary for tirbanibulin production, including the cost of tirbanibulin production, tirbanibulin plant cost, tirbanibulin production costs, and the overall tirbanibulin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a tirbanibulin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Tirbanibulin is a topical microtubule inhibitor and Src kinase signalling blocker primarily indicated for treating non-hyperkeratotic actinic keratosis (AK). It is used on the face or scalp in adults, where it promotes lesion clearance in 44-54% of patients by day 57 through cell cycle arrest and apoptosis in proliferating keratinocytes. It is applied as a 1% ointment once daily for five days. It offers a shorter regimen with milder local skin reactions compared to alternatives like 5-FU or imiquimod. It is suitable for field cancerisation therapy to prevent progression to squamous cell carcinoma. It also shows anti-tumour effects in breast and prostate cancers, as well as management of non-melanoma skin cancers (e.g., basal cell carcinoma, Bowen disease). It also finds its applications in anogenital warts and vulvar intraepithelial neoplasia.
The market for tirbanibulin is driven by its status as a first-in-class topical treatment for actinic keratosis on the face or scalp. The growing incidences of UV-induced precancerous skin lesions amid ageing populations, and rising dermatology awareness fuels its market. Its patient-friendly 5-day application regimen offering high clearance rates with milder skin reactions than alternatives like fluorouracil or imiquimod boosts its demand.
The FDA approval expansions for larger treatment areas up to 100 cm² and Almirall's promotional efforts in key regions like North America and Europe support its market. The premium pricing as a branded product, competition from cheaper generics, cryotherapy, or photodynamic therapy, and supply chain reliance on the manufacturer's stability influence industrial tirbanibulin procurement.
Raw Material for Tirbanibulin Production
According to the tirbanibulin production plant project report, the key raw materials used in the production of tirbanibulin include methyl 2-(5-bromopyridin-2-yl)acetate, 4-hydroxyphenylboronic acid, and 2-(2-chloroethoxy)morpholine.
Production Process of Tirbanibulin
The extensive tirbanibulin production cost report consists of the following major industrial production process:
- From methyl 2-(5-bromopyridin-2-yl)acetate: The production process of tirbanibulin involves several steps. First, methyl 2-(5-bromopyridin-2-yl)acetate is coupled with 4-hydroxyphenylboronic acid via a palladium-catalysed Suzuki reaction. It takes place using an inorganic base to give methyl 2-[5-(4-hydroxyphenyl)pyridin-2-yl]acetate. This phenolic ester is then O-alkylated with a 2-haloethoxy morpholine to introduce the morpholinoethoxy side chain and form methyl 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetate. Finally, this ester undergoes aminolysis with benzylamine in an organic solvent in the presence of 2-pyridone or 6-chloro-2-pyridone as a catalyst to give tirbanibulin as the final product.
Tirbanibulin is a synthetic small-molecule microtubule inhibitor that appears as a white to off-white 1% ointment for topical use. It has a molecular formula of C26H29N3O3 with a molecular weight of 431.54 g/mol (average). Its structure includes a pyridine core, benzyl amide, and morpholinoethoxy side chain. It shows high lipophilicity with a predicted pKa around 6.63 (basic), physiological charge of 0, one hydrogen bond donor, five acceptors, nine rotatable bonds, with a polar surface area of 63.69 Ų. It has the refractivity of 124.86 nm³/mol, and polarizability of 48.49 ų. It supports good skin penetration and stability in ointment bases containing mono- and di-glycerides plus propylene glycol.
